The 200 billion leader has rarely fell, and the concept of CXO has plummeted!Is this administrative order signed by Biden?

On September 13, the concept of CXO performed a low performance throughout the day and led the two cities.

The transaction market showed that Kang Long turned over 10%in the early trading, Kaile Britain fell more than 9%in early trading, and Yaoming Kangde also approached the daily limit in early trading. As of the closing of the day, Yao Ming Kang's limit price was 76.35 yuan/share, and Kai Laiying's limit price was 150.85 yuan/share.

Image source: Wind screenshot

In addition to Yaoming Kant, Yaoming Hong Kong Stocks Company Yaoming Biological and Yin Ming Kant also plummeted. The transaction market shows that Yaoming Bio opened sharply by 7.42%on September 13. After the opening of the company, the company's stock price rapidly exposed, and the market once fell more than 20%. After that, it maintained a low volatile trend throughout the day. Falling 19.94%, the stock price was reported at HK $ 53.4/share. Yaoming Kant H shares also maintained a low volatile trend throughout the day. As of the closing of September 13, the company's stock price reported at HK $ 68.75/share, closing 16.82%.

Among the above -mentioned stocks, Yao Ming Kangde has the highest attention. The company's latest market value is 226 billion yuan. In just one trading day, the company's market value evaporates 20.5 billion yuan.

Medical expert Wei Zimeng told a reporter from Beijing Business Daily that CXO is commonly known as pharmaceutical outsourcing, which is mainly divided into three links: CRO, CMO/CDMO, and CSO. , Sales outsourcing.

According to the post -trading information disclosed by the exchange in the evening, the game of Yaoming Kangde Institution was fierce. The two institutions bought a total of 227 million yuan, and the two institutions sold for a total of 383 million yuan. Out of 135 million yuan.

On the news, the US President Biden signed an administrative order on September 12 to launch a national biotechnology and biological manufacturing initiative to reduce the United States' dependence on foreign countries and ensure that the United States can transform all invention and creation into products to respond China's challenges in biotechnology.

Regarding the above news, Mao Ning, a spokesman for the Chinese Ministry of Foreign Affairs, said at a regular press conference on September 13 that "economic globalization is an objective fact and a historical trend. We hope that the United States will respect the principles of market economic laws and fair competition. The ground hinders global scientific and technological exchanges and trade exchanges. "

In response to the above news, a number of CXO concept stocks also responded.

Yaoming Kant said to the outside world that the company also paid attention to the above information, and the company's business and operations were normal.

Kang Longhua replied to investors on the interactive platform that the company has not learned more details about the United States preparing to launch a biological -related industrial support policy, and the company's business has not been affected by relevant news.

Image source: Shenzhen Stock Exchange Interactive Screenshot

Kai Laiying said that the company has no cooperation in the United States. The company has only cooperation in small molecularized drugs in the United States. Biopharmaceuticals have business in China, and the company's business and operations are normal.

Reporter 丨 horse replacement

Edit 丨 Zhang Lan

Image 丨 Shenzhen Stock Exchange Interactive Easy Screenshot, Wind screenshot, one picture network

- END -